Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy

Trikafta. Trikafta (elexacaftor/tezacaftor/ivacaftor) is a combination CFTR modulator therapy that was approved by the Food and Drug Administration for people with CF who have at least one F508del

dnase
pulmozyme
elexacaftor
ivacaftor
forced expiratory volume
  • 55 views
  • 26 Jan, 2021
  • 74 locations
Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination therapy in CF subjects

  • 0 views
  • 23 Sep, 2021
  • 17 locations
Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)

RECOVER is a prospective, multicenter observational study designed to measure the real world clinical effectiveness of elexacaftor, tezacaftor and ivacaftor triple combination therapy (Kaftrio

elexacaftor
tezacaftor
ivacaftor
spirometry
fibrosis
  • 52 views
  • 12 Jul, 2021
  • 8 locations
The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis

This proposed pilot study will assess if the Patch Technology system will increase adherence in patients with cystic fibrosis followed at the UTHSCSA Cystic Fibrosis Center.

  • 0 views
  • 11 Mar, 2021
  • 1 location
Home-Reported Outcomes in People With Cystic Fibrosis Taking Highly Effective CFTR Modulator Therapy

This is an observational cohort study, using data from Folia Health and the Cystic Fibrosis Foundation Patient Registry (CFFPR). Individuals taking elexacaftor/tezacaftor/ivacaftor (ETI) may be

ivacaftor
elexacaftor
tezacaftor
fibrosis
  • 0 views
  • 22 Sep, 2021
  • 1 location
Impact of Triple Combination CFTR Therapy on Sinus Disease.

The study's main goal is to observe how effective elexacaftor-tezacaftor-ivacaftor is for improving the symptoms and signs of CF-related sinus disease.

  • 0 views
  • 19 Mar, 2021
  • 1 location
A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis

This study will evaluate the performance of wearable technology in cystic fibrosis (CF) participants taking commercial Elexacaftor (ELX)/Tezacaftor (TEZ)/Ivacaftor (IVA) utilizing a fully

forced expiratory volume
elexacaftor
tezacaftor
ivacaftor
fibrosis
  • 0 views
  • 09 Sep, 2021
  • 17 locations
The PROMISE Pediatric Study 6 to 11 Years Old

This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in

ivacaftor
elexacaftor
tezacaftor
fibrosis
  • 0 views
  • 25 Jul, 2021
  • 20 locations
Gut Imaging for Function & Transit in CF - GIFT-CF 3

An observational study of patients with cystic fibrosis (CF) starting treatment with Kaftrio (Elexacaftor / Tezacaftor / Ivacaftor) as part of routine clinical care, following EMA licensing

sweat test
elexacaftor
ivacaftor
diagnostic procedures
fibrosis
  • 0 views
  • 07 Aug, 2021
  • 1 location
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).

cystic fibrosis transmembrane conductance regulator
elexacaftor
tezacaftor
ivacaftor
fibrosis
  • 0 views
  • 16 Jul, 2021
  • 31 locations